Home Page
News
research
Publications
People
Lab Tour
collaborators
Openings




Rangaramanujam M. Kannan, PhD

Professor

Ophthalmology, Johns Hopkins Medicine.

Phone : (443) 287-8634
Email: krangar1@jhmi.edu


Curriculum Vitae: pdf



Education:
B.E. (Hons.): Birla Institute of Technology and Science, 1987
Ph.D.: California Institute of Technology, 1994
Postdoctoral Associate: University of Minnesota, 1994-1995


Awards and Honors:
Director, Nanotechnology Lab, NICHD Perinatology Research Branch, 2008-
NIH Study section membership (NCI Special Emphasis Panels, IMST W53 SBIR)
Editorial Board, NanoMedicine: Nanotechnology, Biology and Medicine
Ralph C. Wilson Foundation Scholar (2007)
Fellow, The American Academy of Nanomedicine, 2006-
NSF CAREER Award (1999)
3M Non-tenured Faculty Award (1998 ?2000, 2001-2002)
Wayne State University Faculty Research Award (1997-1998, 1998-1999)
Unilever Award for outstanding Ph.D. thesis in polymer Science by ACS (1995)
American Chemical Society Honor symposium for Unilever award (1995)
Charles Lee Powell Foundation Graduate Fellowship at Caltech (1992-1994)
Du Pont Graduate Fellowship at Caltech (1989 ?1990)


Research Interests:
Development of dendrimer/hyperbranched polymer based targeted drug delivery systems (Applications to the diseases of the central nervous system): Synthesis, in-vitro, in-vivo characterization, microscopy
click here for more info

Targeted therapeutics for Neurodegenerative disesase such as Cerebral Palsy, AMD and Retinal Degenaration
click here for more info

Development of method to produce highly dispersed, highly reinforced polymer clay nanocomposites utilizing a patented supercritical carbon dioxide process
click here for more info


Click here for a full list of publications

Selected Publications
 
  1. Dendrimer-Based Postnatal Therapy for Neuroinflammation and Cerebral Palsy in a Rabbit Model.Sujatha Kannan, Hui Dai, Raghavendra S. Navath, Bindu Balakrishnan, Amar Jyoti, James Janisse, Roberto Romero, Rangaramanujam M. Kannan* (2012). Science Translational Medicine, Vol. 4, Issue 130, p. 130ra46
     
  2. Intrinsic targeting of neuroinflammation by polyamidoamine dendrimers in a rabbit model of cerebral palsy. H.Dai, R.Navath, B.Balakrishnan, B.Raja Guru, M.Mishra, R.Romero, R.M.Kannan*, S.Kannan*, in press, Future Medicine:Nanomedicine, June. (2010) (journal impact factor:6.05).
     
  3. Amino acid functionalized dendrimers with hetero-bifunctional chemoselective peripheral groups for drug delivery. R.Navath, A.Menjoge, B.Wang, R.Romero, S.Kannan, R.M.Kannan*, DOI: 10.1021/bm100186b, Biomacromolecules, May (2010) (journal impact factor:4.2) .
     
  4. Transport and Biodistribution of Dendrimers Across Human Fetal Membranes: Implications for Intravaginal Administration of Dendrimers? A. R. Menjoge, R. S. Navath, A. Asad, S. Kannan, C. J. Kim, R.Romero, R. M. Kannan*, Biomaterials, 31(8), 5007-5021 (2010) (journal impact factor:6.6).
     
  5. Dendrimer-Based Drug and Imaging Conjugates: Design Considerations for Nanomedical Applications. A.Menjoge, R.M.Kannan*, D.Tomalia*, Invited Foundation review, Drug Discovery Today, 15(5),171-185 (2010) (journal impact factor: 7.1).
     
  6. Multifunctional Dendrimer-templated Antibody Presentation on Biosensor Surfaces for Improved Biomarker Detection? H.Han, R.M.Kannan*, S.Wang, G.Z.Mao, J.P.Kusanovic, R.Romero, Advanced Functional Materials , 19, 1?3 (2009) (journal impact factor: 7.5).
     
  7. Drug release mechanisms and kinetics from dendrimer-drug conjugates with glutathione sensitive linkers. Emre, YK, R. Navath, B. Wang, R. Romero, S. Kannan, RM Kannan*, Biomaterials, 30, 2112-2121 (2009) (journal impact factor:6.6).
     
  8. Supercritical CO2-processed dispersed polystyrene-clay nanocomposites. Manitiu, R. Bellair, S. Horsch, E. Gulari and R. M. Kannan*, Macromolecules, 41,8038-8046, 2008 (journal impact factor:4.4).
     
  9. Dendrimer Effect of surface functionality on the cellular trafficking of dendrimers. O. Pillai, R. Inapagolla, RM.Kannan, S.Kannan*, Biomaterials (2008), 29(24-25), 3469-3476 (2008) (journal impact factor: 6.6).
     
  10. Activity of dendrimer-methotrexate conjugates in sensitive and resistant cell lines? S. Gurdag, J. Khandare, S. Staples, R. M. Kannan*, L. Matherly, Bioconjugate Chem. (2006), 17(2):275-83 (among the top 10 most accessed articles during that period, Faculty of 1000 publication, highlighted by NIH (Nano) and other publications) (journal impact factor: 4.4).